Roche Presents New Data For Ocrevus And Fenebrutinib

ROCHE HOLDING AG RO:

• ROCHE PRESENTS NEW DATA FOR OCREVUS AND FENEBRUTINIB ACROSS BROAD PATIENT POPULATIONS AT ECTRIMS 2025

• ROCHE HOLDING AG - OCREVUS SUBCUTANEOUS MAINTAINS CONSISTENT BENEFIT-RISK PROFILE

• ROCHE HOLDING AG - OCREVUS REDUCES DISABILITY PROGRESSION IN ADVANCED PPMS

• ROCHE HOLDING AG - FENEBRUTINIB SUPPRESSES DISEASE ACTIVITY AT 96 WEEKS

• ROCHE HOLDING AG - OCREVUS DELAYS DISABILITY PROGRESSION AND IMPROVES LIMB FUNCTION

• ROCHE HOLDING AG - OCREVUS REDUCES DISABILITY PROGRESSION RISK BY 30% IN PPMS